| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T19 |
0-159 |
Sentence |
denotes |
Two preparations of enzyme replacement therapy (ERT) -agalsidase alfa and agalsidase beta- with recombinant α-galactosidase was approved in Europe in 2001 [5]. |
| T20 |
160-255 |
Sentence |
denotes |
Agalsidase beta is the only ERT approved by the US Food and Drug Administration since 2003 [6]. |
| T21 |
256-467 |
Sentence |
denotes |
Migalastat (Galafold®) was approved in Europe in May 2016, in Canada in September 2017, in Japan in March 2017 and in the USA in August 2018 for long-term treatment of FD in adults with an amenable mutation [7]. |
